Personalis Inc. (PSNL)
Personalis Inc. (PSNL) Stock Price, Analysis & Data
| Bid | 9.7 |
| Market Cap | 1.5B |
| Revenue (ttm) | 69.67M |
| Net Income (ttm) | -107.18M |
| Beta | 2.29 |
| EPS (ttm) | -1.09 |
| PE Ratio (ttm) | n/a |
| Forward PE | -14.91 |
| P/B (ttm) | 6.35 |
| P/S (ttm) | 21.51 |
| Earnings Date | Nov 3, 2026 |
| Ask | 17.35 |
| Volume | 1,038,769 |
| Avg. Volume (20D) | 3,876,056 |
| Open | 14.11 |
| Previous Close | 14.42 |
| Day's Range | 13.92 - 14.29 |
| 52-Week Range | 4.44 - 16.39 |
| Analyst | Buy |
| Price Target | 14.62 (4.13%) |
| Dividends | n/a |
| Ex-Dividend Date | n/a |
About PSNL
Personalis, Inc. develops, markets, and sells advanced cancer genomic tests and services in the United States and internationally. The company offers NeXT Personal, a tumor-informed liquid biopsy test for detection of minimal residual disease (MRD), therapy response and recurrence monitoring in solid tumor cancers; and ImmunoID NeXT, a tissue-based service that combines whole exome and whole transcriptome sequencing data with advanced analytics t...
Financial Performance
In 2025, Personalis's revenue was 69.65M, a decrease of -17.69% compared to the previous year's 84.61M. Earnings were -81.27M, a decrease of -0.02%.
Financial StatementsAnalyst Forecast
According to 4 analyst ratings, the average rating for PSNL stock is "Buy". The 12-month stock price forecast is 14.62, which is upside of 4.13% from the latest price.
Stock ForecastsEarnings Surprise
Analysts project revenue of ... Upgrade
